Akoya Biosciences Inc

Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational and clinical research. The company was founded by Garry Nolan, Yury Goltsev and Nikolay Samusik in 2015 and is headquartered in Marlborough, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Akoya Biosciences achieves record revenue, eyes strategic growth initiatives

Akoya Biosciences reported impressive financial performance and outlined strategic priorities for 2023, focusing on revenue growth and operational enhancements.
While facing challenges like anemic reagent revenue and increasing expenses, the company remains optimistic about its position for growth and market opportunities.
With a strong emphasis on partnerships, product innovation, and revenue diversification, Akoya is poised to leverage its strengths and navigate challenges for sustained success.

Akoya Biosciences reports record Q1 revenue and eyes sustained growth

Akoya Biosciences' Q1 performance reflects strong revenue growth and strategic focus on sustained high growth.
The company aims for cash flow positivity by 2025 through targeted spending and revenue growth.
Challenges include successful Fusion 2.0 upgrades and driving reagent growth, balanced with maintaining high performance.
Opportunities lie in upgrading customers, partnerships, and innovative solutions driving revenue growth.

Akoya Biosciences reports record Q2 revenue and strategic growth plans

Akoya Biosciences excelled in Q2 2023 with record revenue and system placements, showcasing strength in spatial biology solutions.
The company's focus on reagent revenue growth, system upgrades, and revenue guidance highlights a strategic path for future growth.
While facing challenges in gross margins and adoption methodologies, Akoya's investments and opportunities position it well for continued success.

Akoya Biosciences excels in Q3, eyes sustained growth and efficiency

Akoya Biosciences delivered a standout performance in Q3 2023, marked by record revenue and gross profit, supported by a robust install base and strategic initiatives.
The company's strengths lie in workflow efficiency enhancements, strong gross margins, and a clear growth strategy through services and partnerships.
Challenges include achieving cash flow positivity, sustaining margins, and driving adoption of new solutions, while opportunities abound in genomics, partnerships, and market expansion.
Overall, Akoya's focus on innovation, efficiency, and market positioning sets a solid foundation for continued growth and financial success.

Akoya Biosciences reports record-breaking revenue and strategic partnerships for growth

Akoya Biosciences delivered impressive financial performance in Q4 2023, showcasing revenue growth, cost management, and strategic investments. While facing challenges from macro pressures and underperformance in certain regions, the company remains focused on achieving cash flow breakeven by 2024. Akoya's strengths in partnerships and product enhancements position them well for continued growth and margin expansion.

Akoya Biosciences reports Q1 revenue decline but eyes growth opportunities

Akoya Biosciences faced revenue decline in Q1 due to weak instrument placements but saw growth in reagent and services revenue, aiming for breakeven by year-end.
The company updated its 2024 revenue outlook, expecting a measured recovery and sustained growth, with opportunities in partnerships and margin improvement initiatives.
Challenges include academic budget assumptions impacting revenue guidance and increasing outsourcing to CROs affecting reagent growth opportunities.
Despite challenges, Akoya's strengths lie in strong reagent revenue growth, strategic partnerships, and potential for achieving higher gross margins in the future.

Akoya Biosciences reports strong Q2 revenue growth and eyes market expansion

Akoya Biosciences demonstrated robust revenue growth in Q2 2024, driven by strong performance across instrument, reagent, and service segments.
While facing challenges in revenue guidance adjustments and delayed impact from NMPA approval in China, Akoya's strategic initiatives and product strengths offer promising opportunities for future growth.
Overall, Akoya's focus on financial goals, product innovation, and market expansion sets a positive trajectory for the company's performance and competitiveness in the biotech sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Q3 2022 revenue $18.9 million, 40% y/y growth Raising FY 2022 revenue guidance range to $73-75 million

Akoya Reports Record Revenue with 40% YoY Growth in the Third Quarter and Raises Full Year 2022 Revenue Guidance

Each panel focuses on distinct areas of tumor biology and response to therapy which are of greatest interest to translational and clinical researchers

Akoya Biosciences Launches PhenoCode Signature Panels to Accelerate Development of Predictive Biomarkers for Cancer Immunotherapy

MARLBOROUGH, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2022 after the market close on Monday, November 7th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Akoya to Report Third Quarter 2022 Financial Results on November 7th, 2022

MARLBOROUGH, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in four upcoming investor conferences.

Akoya to Participate at Four Upcoming Investor Conferences

Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q2 2022 Earnings Conference Call August 8, 2022 5:00 PM ET Company Participants Priyam Shah - Head of IR Brian McKelligon - CEO Joseph Driscoll - CFO Conference Call Participants Neil Vibhakar - Morgan Stanley Kyle Mikson - Canaccord Genuity Mark Massaro - BTIG David Westenberg - Piper Sandler Operator Thank you for standing by, and welcome to the Akoya Biosciences Second Quarter 2022 Earnings Conference Call. At this time, all participants are in listen-only mode.

Title: Akoya Biosciences, Inc. (AKYA) CEO Brian McKelligon on Q2 2022 Results - Earnings Call Transcript

Q2 2022 revenue $17.9 million, 37% y/y growth Raising FY 2022 revenue guidance range to $71-74 million

Akoya Reports Second Quarter 2022 Operating Results and Raises Full Year 2022 Revenue Guidance

MARLBOROUGH, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of 2022 after the market close on Monday, August 8th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Akoya to Report Second Quarter 2022 Financial Results on August 8th, 2022

The OncoSignature® test developed based on Acrivon's AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced Phase 2 targeted oncology agent for solid cancers

Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon's Proprietary OncoSignature® Test into a Companion Diagnostic

PhenoCycler™-Fusion will enable single-cell, whole-slide spatial multiomic capabilities on a single platform PhenoCycler™-Fusion will enable single-cell, whole-slide spatial multiomic capabilities on a single platform

Akoya Biosciences to Highlight Novel Spatial Transcriptomics Capabilities on PhenoCycler-Fusion at AGBT 2022 Annual Meeting

Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Priyam Shah - Head of IR Brian McKelligon - CEO Joe Driscoll - CFO Conference Call Participants Dave Westenberg - Piper Sandler Edmund Tu - Morgan Stanley Operator Welcome to the Akoya Biosciences First Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, today's call is being recorded.

Akoya Biosciences, Inc. (AKYA) CEO Brian McKelligon on Q1 2022 Results - Earnings Call Transcript

Q1 2022 revenue $16.9 million, 38% growth over prior year period Raising FY 2022 revenue guidance range to $70-73 million

Akoya Reports First Quarter 2022 Operating Results and Raises Full Year 2022 Revenue Guidance

Dr. El-Gabry's extensive leadership experience will be critical to accelerating Akoya's groundbreaking spatial biomarker research technologies into clinical tools that will impact patient care Dr. El-Gabry's extensive leadership experience will be critical to accelerating Akoya's groundbreaking spatial biomarker research technologies into clinical tools that will impact patient care

Akoya Biosciences Announces Ehab A. El-Gabry, MD, as Chief Medical Officer

MARLBOROUGH, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2022 after the market close on Thursday, May 5th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Akoya to Report First Quarter 2022 Financial Results on May 5th, 2022

MARLBOROUGH, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced that two important milestones on advancing the speed and scale of its spatial phenotyping solutions, will be presented during the American Association for Cancer Research (AACR) 2022 Annual Meeting in New Orleans, April 8 to 13. First, the company will showcase the industry's first 100-plex dataset for deep spatial phenotyping at single cell resolution, across an entire tissue sample. Second, they will preview a new universal chemistry to enable accelerated validation of biomarkers discovered using deep spatial phenotyping.

Akoya Biosciences to Showcase New Data on PhenoCycler-Fusion at the AACR Annual Meeting 2022

Akoya Biosciences, Inc. (AKYA) CEO Brian McKelligon on Q4 2021 Results - Earnings Call Transcript

Q4 2021 revenue $16.2 million and FY 2021 revenue $54.9 million FY 2022 revenue guidance $69 - 71 million

Akoya Reports Fourth Quarter and Full Year 2021 Operating Results and Provides 2022 Financial Outlook

MARLBOROUGH, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fourth quarter and full year of 2021 after the market close on Monday, March 14th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Akoya to Report Fourth Quarter and Full Year 2021 Financial Results on March 14th, 2022 and Present at the Cowen Annual Health Care Conference on March 8th, 2022

Akoya Biosciences (AKYA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Akoya Biosciences (AKYA) This Earnings Season?

MARLBOROUGH, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be virtually participating in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Akoya Biosciences to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Ms. Moy brings 30 years of HR leadership experience at high-performing companies Ms. Moy brings 30 years of HR leadership experience at high-performing companies

Akoya Biosciences Appoints Marilee Moy as Chief People Officer

Powered by novel technology that can map a million cells in 10 minutes, the system enables unbiased spatial discovery across whole slides, at scale Powered by novel technology that can map a million cells in 10 minutes, the system enables unbiased spatial discovery across whole slides, at scale

Akoya Biosciences Announces Commercial Launch of PhenoCycler-Fusion, the Fastest Single-Cell Spatial Biology System

MARLBOROUGH, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2021.

Akoya Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021

Alnylam Pharmaceuticals

Biohaven Pharmaceutical Hld

Sanofi

These biotech stocks could be worth watching in 2022.

Which Stocks To Buy Now? 4 Biotech Stocks To Know

Akoya's powerful new PhenoCycler™-Fusion system combined with Bio-Techne's proven and established RNAScope® technology will enable comprehensive spatial phenotyping of RNA and protein biomarkers Akoya's powerful new PhenoCycler™-Fusion system combined with Bio-Techne's proven and established RNAScope® technology will enable comprehensive spatial phenotyping of RNA and protein biomarkers

Akoya Biosciences and Bio-Techne Partner to Deliver Automated Spatial Multiomics Workflow with Industry-Leading Speed and Resolution

Bio-Techne

MINNEAPOLIS  and MARLBOROUGH, Mass., Jan. 5, 2022 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, today announced a partnership to develop the first single-cell, spatial multiomics workflow for comprehensive, unbiased analysis of tissue samples.

News for Akoya Biosciences Inc Stock (AKYA)